Niagen Bioscience (NAGE) Enterprise Value (2011 - 2026)

Niagen Bioscience (NAGE) has reported Enterprise Value for 12 consecutive years, with -$66.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 19.66% year-over-year to -$66.5 million; the TTM figure through Mar 2026 stood at -$66.5 million (down 19.66% YoY), while the FY2025 annual figure was -$64.8 million, down 45.07% from the prior year.
• Enterprise Value declined to -$66.5 million in Q1 2026 per NAGE's latest filing, from -$64.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$13.3 million in Q3 2022 and bottomed at -$66.5 million in Q1 2026.
• Historically, Enterprise Value has averaged -$36.4 million across 5 years, with a median of -$27.6 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 59.94% — and 2025, when it plunged 116.87%.
• Niagen Bioscience's Enterprise Value stood at -$20.4 million in 2022, then sank by 33.68% to -$27.3 million in 2023, then tumbled by 63.44% to -$44.7 million in 2024, then sank by 45.07% to -$64.8 million in 2025, then declined by 2.72% to -$66.5 million in 2026.
• Business Quant data shows NAGE's Enterprise Value at -$66.5 million in Q1 2026, -$64.8 million in Q4 2025, and -$64.3 million in Q3 2025.